Modality Services

We provide integrated solutions for site-specific conjugation and linker-payload optimization to create highly stable, potent antibody-drug conjugates for targeted research.

Our platform offers diverse bispecific antibody formats and assembly strategies to enable dual-target recognition and enhanced immune cell recruitment in complex research models.

We offer specialized scFv engineering and optimized viral vector services to enhance the persistence, specificity, and anti-tumor performance of novel cellular research candidates.

We utilize enzyme-mediated surface tagging to live-label and identify tumor-specific T cells, enabling the rapid discovery of high-affinity TCRs for advanced research applications.

We deliver precise quantitative analysis of antibody-antigen kinetics using SPR and BLI technologies to characterize binding affinity and interaction dynamics for immune checkpoint research.

We provide diverse cell-based assays, including reporter gene, cytokine release, and proliferation tests, to validate the antagonistic or agonistic activity of checkpoint-targeting biologics.

Our specialized library screening technology enables the rapid identification of high-affinity binders against challenging target epitopes, including post-translationally modified proteins and complex receptors.

We provide a flexible scaffold platform for the rapid assembly of multispecific antibodies and fusion proteins, ensuring high stability and balanced affinity for complex research goals.

We offer advanced polymeric micelle encapsulation to enhance the solubility and targeted delivery of hydrophobic payloads, ensuring controlled release and improved pharmacokinetics in research.

We provide a prodrug technology platform that utilizes tumor-microenvironment-specific enzymes to trigger the selective release of potent payloads, maximizing research efficacy while minimizing off-target interaction.

We provide high-sensitivity imaging solutions using specialized PET tracers to monitor T-cell activation and distribution, facilitating real-time evaluation of therapeutic responses in advanced research models.

We utilize hyperimmunized mammalian milk to produce large-scale, cost-effective polyclonal IgG, providing oral or systemic passive immunity for diverse infectious and research applications.

We integrate specialized microRNA clusters into CAR-T cells to silence inhibitory genes, enhancing cellular persistence and overcoming the immunosuppressive microenvironment in advanced research settings.

We offer comprehensive immunomonitoring to quantify and characterize regulatory T cells within tumors, assessing the impact of checkpoint inhibitors on the immunosuppressive microenvironment.

We provide comprehensive profiling of genomic, proteomic, and microenvironmental biomarkers to predict responsiveness to checkpoint therapies and optimize patient selection for research models.

We provide automated, large-scale expression and purification of thousands of recombinant antibodies simultaneously, delivering high-purity candidates for rapid screening and discovery research.

We provide high-throughput mass spectrometry and computational modeling to identify and validate tumor-specific neoantigens presented by HLA complexes for personalized immunotherapy research.

We provide advanced transcriptomic profiling to identify specific T-cell gene signatures, enabling precise evaluation of immune states and therapeutic efficacy in research models.

We utilize specialized HLA-typing and screening platforms to identify novel cancer targets and engineer high-affinity, specific TCRs for next-generation adoptive cell research.

We design and validate specialized pairs of monoclonal antibodies targeting distinct pathways to evaluate synergistic effects and therapeutic potential in complex disease research.

We offer specialized nanotechnology platforms to engineer multivalent NK cell engagers, enhancing natural killer cell recruitment and tumor-killing activity in advanced research models.

We provide specialized fusion protein engineering to link cytokines with antibodies, enabling targeted delivery and localized immune activation within the tumor microenvironment for research.

We provide specialized site-specific PEGylation services to extend half-life, reduce immunogenicity, and optimize the pharmacokinetic profiles of therapeutic cytokines for research.

We provide high-content screening using bead-based technology to simultaneously detect multiple cytokines and cell-surface markers, enabling comprehensive immune profiling for research.